Resverlogix Corp. TSX: RVX October 7th, 2009.

Slides:



Advertisements
Similar presentations
May 13, TSX-V:OCO, Frankfurt:OR6, US OTC: ORRCF.
Advertisements

Line Efficiency     Percentage Month Today’s Date
Jan 2016 Solar Lunar Data.
IT Strategy Roadmap Template
Scholarship Submission Calendar
Monthly Report For January 2017

Q1 Jan Feb Mar ENTER TEXT HERE Notes
Comparative Statistics September 2017

Project timeline # 3 Step # 3 is about x, y and z # 2
Average Monthly Temperature and Rainfall
<Location> – <Project Name>, Sponsor: <name>

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.





2017 Jan Sun Mon Tue Wed Thu Fri Sat


FOMEMA Sales Review Clinic Management Meeting
2013 VFC PRESIDENT’S REPORT
Gantt Chart Enter Year Here Activities Jan Feb Mar Apr May Jun Jul Aug
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Free PPT Diagrams : ALLPPT.com


Proposed Strategic Planning Process for FY 2013/14 thru FY 2015/16

Calendar Year 2009 Insure Oklahoma Total & Projected Enrollment
MONTH CYCLE BEGINS CYCLE ENDS DUE TO FINANCE JUL /2/2015
Jan Sun Mon Tue Wed Thu Fri Sat



©G Dear 2008 – Not to be sold/Free to use


Electricity Cost and Use – FY 2016 and FY 2017


Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Operations Management Dr. Ron Lembke
Text for section 1 1 Text for section 2 2 Text for section 3 3
B.E.E BitcoinEnterpriseExchange.com
Text for section 1 1 Text for section 2 2 Text for section 3 3
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Free PPT Diagrams : ALLPPT.com


Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Gleichen Resources TSXV: GRL October 7th, 2009.
Capella Resources Ltd TSX.V: KPS December 15, 2009.
Year of Wellbeing campaign activity Jan Feb Mar Apr May Jun
Project timeline # 3 Step # 3 is about x, y and z # 2
TIMELINE NAME OF PROJECT Today 2016 Jan Feb Mar Apr May Jun
WGI Heavy Minerals Inc. TSX:WG April 16, 2009.

Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
TSX: OPC May 13, 2009.
Key Management Processes
Presentation transcript:

Resverlogix Corp. TSX: RVX October 7th, 2009

About Company Resverlogix based in Calgary-based TSX-list biotech company that is a world-leader in the development of an oral therapy to actually regress plaque build-ups in a person’s arteries. Plaque build-up also known as atherosclerosis, is the leading cause of cardiovascular disease (CVD), the leading killer of men and women in the industrialized world with over 18 million deaths reported in 2005 (World Health Organization).

About Company NexVas™ Plaque Regression (NexVas PR), is a novel technology platform with drugs that increase apolipoproteinA-I (ApoA-I) to reduce atherosclerosis (fatty plaque build-up in the arteries), which is the leading cause of CVD. ApoA-I is the key protective protein of high density lipoprotein (HDL), commonly known as the “good cholesterol”. Current drugs on the market only manage atherosclerosis burden but they have very limited or no effect on atherosclerosis regression. NexVas PR aims to manage and regress atherosclerosis. Resverlogix’s lead ApoA-I drug RVX-208 recently completed a Phase 1b/2a human clinical trial.

Management Donald J. McCaffrey President and CEO, Co-Founder Don is Resverlogix’s strategic leader, founder, mentor and the overall ‘heart’ of the company. Norman C.W. Wong, M.D., FRCP Chief Scientific Officer & Co-Founder Norman is the visionary for the scientific development of Resverlogix’s therapeutic platforms. Jan O. Johansson, M.D., Ph.D. Senior Vice President Medical Affairs Jan oversees the clinical and regulatory development, and provides scientific guidance to the corporation.

Management Kenneth Lebioda, BA Senior VP Business & Corporate Development Ken is responsible for the business and market development of the company’s technology pipeline and alliance management. Gregory S. Wagner, Ph.D., DABT Senior VP Research & Development Greg oversees the company’s preclinical programs and provides extensive expertise in the areas of drug development, regulatory filings, and toxicology. Dr. F. Allan Gordon, M.D., Ph.D Senior Vice President of Clinical Development Allan will lead Resverlogix through clinical development.

Share Structure & Financials Shares Outstanding: 39.4M Shares Fully Diluted: 49.6M Options/Warrants: 10.2M Current Price: $2.81 52 Week High/Low: $6.10/1.50 3 mo daily volume: 73,000 Cash on Hand: $7M

1-Year Stock Chart

Calendar of Catalysts Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec X Sept: Announced successful 1b/2a human clinical trial Nov: Preparation of Stage 2 Human Clinical Trial by IVUS (intravascular ultrasound) Big Pharma could invest at any time

Why Invest Now? Recent US analyst coverage by Rodman & Renshaw with 1-year $8 price target Moving towards a Stage 2 Human Clinical Trial (IVUS) Big Pharma could invest at any time as financing will need to be done prior to IVUS 1-per-cent and 5-per-cent regression of atherosclerosis would save the U.S. health care system between $22.9-billion (U.S.) and $76.8-billion (U.S.) annually

Contact Contact: Graeme A. Dick TSX: RVX Website: www.resverlogix.com Phone: 403-561-8989 Email: graeme@briscocapital.com TSX: RVX